Murine metabolic HFpEF is associated with mitochondrial substrate inflexibility and S-nitrosylation remodeling
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition with incompletely defined myocardial mechanisms. Here, using a two-hit murine model of cardiometabolic HFpEF induced by high-fat diet and endothelial nitric oxide synthase inhibition, we define a mitochondrial metabolic phenotype characterized by substrate inflexibility, redox stress, and S-nitrosylation remodeling. While global proteomic changes were modest, metabolomic profiling revealed accumulation of tricarboxylic acid cycle intermediates, increased dicarboxylic acids, and altered redox-associated metabolites, consistent with inefficient oxidative metabolism and mitochondrial redox imbalance in this experimental setting. S-nitrosylation proteomics demonstrated a highly organized and bidirectional remodeling pattern affecting proteins involved in fatty acid/lipid metabolism, carbohydrate metabolism, mitochondrial energy metabolism, amino acid and organic acid metabolism, nucleotide/cofactor metabolism, and redox defense. Beta-hydroxybutyrate (BHB), an alternative mitochondrial substrate, improved basal and ATP-linked respiration, reduced selected TCA-cycle intermediates, lowered mitochondrial reactive oxygen species and the NADH/NAD + ratio, partially restored the GSH/GSSG ratio, and improved diastolic and functional phenotypes without altering preserved ejection fraction. Together, these findings define a redox-sensitive mitochondrial metabolic state in the HFD/L-NAME model and identify ketone supplementation as a partial metabolic rescue strategy in this context. At the same time, they highlight an important limitation of murine HFpEF models: such models do not faithfully reproduce the metabolic phenotype of human HFpEF and should therefore be interpreted as experimental systems rather than human disease equivalents.